Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2020

Details for Mechanism ID: 18504
Country/Region: Kenya
Year: 2018
Main Partner: University of Maryland
Main Partner Program: University of Maryland Baltimore
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $9,399,645 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $588,842
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $897,920
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $2,956
Testing: HIV Testing and Counseling (HVCT) $1,067,890
Sexual Prevention: Other Sexual Prevention (HVOP) $53,084
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $689,071
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $5,469,318
Treatment: Pediatric Treatment (PDTX) $630,564
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_SELF 2019 3,168
HTS_SELF 10-14, Female, Directly-Assisted 2019 8
HTS_SELF 15-19, Female, Directly-Assisted 2019 169
HTS_SELF 15-19, Female, Unassisted 2019 169
HTS_SELF 15-19, Male, Directly-Assisted 2019 57
HTS_SELF 15-19, Male, Unassisted 2019 57
HTS_SELF 20-24, Female, Directly-Assisted 2019 169
HTS_SELF 20-24, Female, Unassisted 2019 169
HTS_SELF 20-24, Male, Directly-Assisted 2019 57
HTS_SELF 20-24, Male, Unassisted 2019 57
HTS_SELF 25-29, Female, Directly-Assisted 2019 169
HTS_SELF 25-29, Female, Unassisted 2019 169
HTS_SELF 25-29, Male, Directly-Assisted 2019 57
HTS_SELF 25-29, Male, Unassisted 2019 57
HTS_SELF 30-34, Female, Directly-Assisted 2019 169
HTS_SELF 30-34, Female, Unassisted 2019 169
HTS_SELF 30-34, Male, Directly-Assisted 2019 57
HTS_SELF 30-34, Male, Unassisted 2019 57
HTS_SELF 35-39, Female, Directly-Assisted 2019 169
HTS_SELF 35-39, Female, Unassisted 2019 169
HTS_SELF 35-39, Male, Directly-Assisted 2019 57
HTS_SELF 35-39, Male, Unassisted 2019 57
HTS_SELF 40-49, Female, Directly-Assisted 2019 169
HTS_SELF 40-49, Female, Unassisted 2019 169
HTS_SELF 40-49, Male, Directly-Assisted 2019 57
HTS_SELF 40-49, Male, Unassisted 2019 57
HTS_SELF 50+, Female, Directly-Assisted 2019 169
HTS_SELF 50+, Female, Unassisted 2019 169
HTS_SELF 50+, Male, Directly-Assisted 2019 57
HTS_SELF 50+, Male, Unassisted 2019 57
HTS_SELF Directly-Assisted 2019 1,588
HTS_SELF FSW, Directly-Assisted 2019 2,117
HTS_SELF MSM, Directly-Assisted 2019 474
HTS_SELF PWID, Directly-Assisted 2019 190
HTS_SELF Unassisted 2019 1,580
HTS_SELF Unassisted - Other 2019 158
HTS_SELF Unassisted - Self 2019 789
HTS_SELF Unassisted - Sex Partner 2019 632
HTS_TST 15-19, Female, Negative 2019 326
HTS_TST 15-19, Male, Negative 2019 349
HTS_TST 20-24, Female, Negative 2019 1,125
HTS_TST 20-24, Male, Negative 2019 1,117
HTS_TST 25-29, Female, Negative 2019 36
HTS_TST 25-29, Female, Negative 2019 126
HTS_TST 25-29, Female, Negative 2019 1,717
HTS_TST 25-29, Female, Negative 2019 4,304
HTS_TST 25-29, Female, Negative 2019 61
HTS_TST 25-29, Female, Negative 2019 53
HTS_TST 25-29, Male, Negative 2019 592
HTS_TST 25-29, Male, Negative 2019 1,783
HTS_TST 25-29, Male, Negative 2019 36,521
HTS_TST 25-29, Male, Negative 2019 776
HTS_TST 25-29, Male, Negative 2019 71
HTS_TST 25-29, Male, Negative 2019 2,100
HTS_TST 30-34, Female, Negative 2019 43
HTS_TST 30-34, Female, Negative 2019 143
HTS_TST 30-34, Female, Negative 2019 1,962
HTS_TST 30-34, Female, Negative 2019 4,304
HTS_TST 30-34, Female, Negative 2019 70
HTS_TST 30-34, Female, Negative 2019 48
HTS_TST 30-34, Male, Negative 2019 710
HTS_TST 30-34, Male, Negative 2019 2,139
HTS_TST 30-34, Male, Negative 2019 43,825
HTS_TST 30-34, Male, Negative 2019 932
HTS_TST 30-34, Male, Negative 2019 76
HTS_TST 35-39, Female, Negative 2019 10
HTS_TST 35-39, Female, Negative 2019 36
HTS_TST 35-39, Female, Negative 2019 490
HTS_TST 35-39, Female, Negative 2019 4,304
HTS_TST 35-39, Female, Negative 2019 17
HTS_TST 35-39, Female, Negative 2019 59
HTS_TST 35-39, Male, Negative 2019 710
HTS_TST 35-39, Male, Negative 2019 2,139
HTS_TST 35-39, Male, Negative 2019 43,825
HTS_TST 35-39, Male, Negative 2019 932
HTS_TST 35-39, Male, Negative 2019 106
HTS_TST 40-49, Female, Negative 2019 10
HTS_TST 40-49, Female, Negative 2019 36
HTS_TST 40-49, Female, Negative 2019 490
HTS_TST 40-49, Female, Negative 2019 4,304
HTS_TST 40-49, Female, Negative 2019 17
HTS_TST 40-49, Female, Negative 2019 48
HTS_TST 40-49, Male, Negative 2019 237
HTS_TST 40-49, Male, Negative 2019 713
HTS_TST 40-49, Male, Negative 2019 14,608
HTS_TST 40-49, Male, Negative 2019 310
HTS_TST 40-49, Male, Negative 2019 97
HTS_TST 50+, Female, Negative 2019 9
HTS_TST 50+, Male, Negative 2019 156
HTS_TST By Key Population: FSW, Negative 2019 411
HTS_TST By Key Population: MSM, Negative 2019 7
HTS_TST By Key Population: PWID, Negative 2019 1
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 384,771
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 324
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 9,083
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 18,706
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 42
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 707
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 1,910
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 662
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 500
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 230
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 270
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 795
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 748
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 5
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 118
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 74
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 212
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 71
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 52
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 724
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 807
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 2,494
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 2,581
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 18
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 356
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 4,744
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 1,615
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 1,197
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 10,321
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 19,651
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 45,100
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 54,008
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 246
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 7,304
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 2,066
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 31
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 37
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 35
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 56
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 68
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 56
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 68
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 45
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 79
HTS_TST Service Delivery Point (Facility) VMMC: 10-14, Negative 2019 2,100
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 3,151
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 3,151
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 1,692
HTS_TST_POS 15-19, Female, Positive 2019 2
HTS_TST_POS 15-19, Male, Positive 2019 1
HTS_TST_POS 20-24, Female, Positive 2019 4
HTS_TST_POS 20-24, Male, Positive 2019 4
HTS_TST_POS 25-29, Female, Positive 2019 5
HTS_TST_POS 25-29, Female, Positive 2019 2
HTS_TST_POS 25-29, Female, Positive 2019 32
HTS_TST_POS 25-29, Female, Positive 2019 549
HTS_TST_POS 25-29, Female, Positive 2019 11
HTS_TST_POS 25-29, Male, Positive 2019 92
HTS_TST_POS 25-29, Male, Positive 2019 34
HTS_TST_POS 25-29, Male, Positive 2019 652
HTS_TST_POS 25-29, Male, Positive 2019 3
HTS_TST_POS 25-29, Male, Positive 2019 15
HTS_TST_POS 25-29, Male, Positive 2019 2
HTS_TST_POS 30-34, Female, Positive 2019 6
HTS_TST_POS 30-34, Female, Positive 2019 2
HTS_TST_POS 30-34, Female, Positive 2019 36
HTS_TST_POS 30-34, Female, Positive 2019 10
HTS_TST_POS 30-34, Male, Positive 2019 110
HTS_TST_POS 30-34, Male, Positive 2019 40
HTS_TST_POS 30-34, Male, Positive 2019 782
HTS_TST_POS 30-34, Male, Positive 2019 4
HTS_TST_POS 30-34, Male, Positive 2019 15
HTS_TST_POS 35-39, Female, Positive 2019 2
HTS_TST_POS 35-39, Female, Positive 2019 9
HTS_TST_POS 35-39, Female, Positive 2019 12
HTS_TST_POS 35-39, Male, Positive 2019 110
HTS_TST_POS 35-39, Male, Positive 2019 40
HTS_TST_POS 35-39, Male, Positive 2019 782
HTS_TST_POS 35-39, Male, Positive 2019 4
HTS_TST_POS 35-39, Male, Positive 2019 22
HTS_TST_POS 40-49, Female, Positive 2019 2
HTS_TST_POS 40-49, Female, Positive 2019 9
HTS_TST_POS 40-49, Female, Positive 2019 10
HTS_TST_POS 40-49, Male, Positive 2019 36
HTS_TST_POS 40-49, Male, Positive 2019 13
HTS_TST_POS 40-49, Male, Positive 2019 261
HTS_TST_POS 40-49, Male, Positive 2019 1
HTS_TST_POS 40-49, Male, Positive 2019 20
HTS_TST_POS By Key Population: FSW, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) ANC: 10-14, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 107
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 479
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 36
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 42
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 114
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 142
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) Inpatient: <1, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 42
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 49
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 42
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 11
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 184
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 351
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 809
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 962
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 130
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) VMMC: 10-14, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) VMMC: 15-19, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) VMMC: 20-24, Positive 2019 3
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 583
KP_PREV By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 8
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 591
PMTCT_ART Already on ART at beginning of current pregnancy 2019 2,869
PMTCT_ART New on ART 2019 1,075
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 3,944
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 49,515
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 723
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 723
PMTCT_EID Sum of Infant Age disaggregates 2019 723
PMTCT_STAT 25-29, Female 2019 6,836
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 506
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 6,135
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 117
PMTCT_STAT 30-34, Female 2019 6,613
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 506
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 6,039
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 117
PMTCT_STAT 35-39, Female 2019 3,236
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 506
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 2,615
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 117
PMTCT_STAT 40-49, Female 2019 3,100
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 506
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 2,598
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 117
PMTCT_STAT By Age (Numerator): 10-14 2019 337
PMTCT_STAT By Age (Numerator): 15-19 2019 9,443
PMTCT_STAT By Age (Numerator): 20-24 2019 19,907
PMTCT_STAT By Age (Numerator): 50+ 2019 43
PMTCT_STAT By Number of known positives: 10-14 2019 6
PMTCT_STAT By Number of known positives: 15-19 2019 168
PMTCT_STAT By Number of known positives: 20-24 2019 821
PMTCT_STAT By Number of new negative: 10-14 2019 322
PMTCT_STAT By Number of new negative: 15-19 2019 9,045
PMTCT_STAT By Number of new negative: 20-24 2019 18,538
PMTCT_STAT By Number of new negative: 50+ 2019 42
PMTCT_STAT By Number of new positives: 10-14 2019 5
PMTCT_STAT By Number of new positives: 15-19 2019 233
PMTCT_STAT By Number of new positives: 20-24 2019 452
PMTCT_STAT Number of new ANC and L&D clients 2019 50,229
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 49,515
PMTCT_STAT_den 25-29, Female 2019 5,429
PMTCT_STAT_den 30-34, Female 2019 5,429
PMTCT_STAT_den 35-39, Female 2019 5,429
PMTCT_STAT_den 40-49, Female 2019 5,429
PMTCT_STAT_den By Age (Denominator): <15-19 2019 10,048
PMTCT_STAT_den By Age (Denominator): 10-14 2019 393
PMTCT_STAT_den By Age (Denominator): 20-24 2019 17,945
PMTCT_STAT_den By Age (Denominator): 50+ 2019 127
PrEP_NEW 25-29, Female 2019 73
PrEP_NEW 25-29, Male 2019 32
PrEP_NEW 30-34, Female 2019 52
PrEP_NEW 30-34, Male 2019 41
PrEP_NEW 35-39, Female 2019 52
PrEP_NEW 35-39, Male 2019 41
PrEP_NEW 40-49, Female 2019 52
PrEP_NEW 40-49, Male 2019 32
PrEP_NEW Female 15-19 2019 125
PrEP_NEW Female 20-24 2019 428
PrEP_NEW Female 50+ 2019 21
PrEP_NEW FSW 2019 146
PrEP_NEW Male 15-19 2019 11
PrEP_NEW Male 20-24 2019 63
PrEP_NEW Male 50+ 2019 21
PrEP_NEW MSM 2019 73
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 1,044
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 416
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 384
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 800
TB_PREV By Age/Sex (Numerator): <15, Female 2019 363
TB_PREV By Age/Sex (Numerator): <15, Male 2019 282
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 4,536
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 1,943
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 7,124
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 8,315
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 420
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 328
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 5,269
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 2,298
TB_PREV_den IPT, Life-long ART, New, Positive 2019 8,315
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 63
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 804
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 78
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 970
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 1,915
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 1,920
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 68
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 794
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 79
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 986
TX_CURR 25-29, Female, Positive 2019 10,452
TX_CURR 25-29, Male, Positive 2019 3,520
TX_CURR 30-34, Female, Positive 2019 7,926
TX_CURR 30-34, Male, Positive 2019 5,503
TX_CURR 35-39, Female, Positive 2019 7,926
TX_CURR 35-39, Male, Positive 2019 5,503
TX_CURR 40-49, Female, Positive 2019 5,405
TX_CURR 40-49, Male, Positive 2019 5,503
TX_CURR Age/Sex: <1 2019 66
TX_CURR Age/Sex: <1-9 2019 3,004
TX_CURR Age/Sex: 10-14 Female 2019 1,133
TX_CURR Age/Sex: 10-14 Male 2019 944
TX_CURR Age/Sex: 15-19 Female 2019 2,148
TX_CURR Age/Sex: 15-19 Male 2019 860
TX_CURR Age/Sex: 20-24 Female 2019 5,992
TX_CURR Age/Sex: 20-24 Male 2019 1,146
TX_CURR Age/Sex: 50+ Female 2019 4,323
TX_CURR Age/Sex: 50+ Male 2019 1,980
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 73,334
TX_CURR Sum of age/sex disaggregates 2019 3,008
TX_NEW 25-29, Female, Positive 2019 19
TX_NEW 25-29, Male, Positive 2019 1,018
TX_NEW 30-34, Female, Positive 2019 61
TX_NEW 30-34, Male, Positive 2019 1,223
TX_NEW 35-39, Female, Positive 2019 15
TX_NEW 35-39, Male, Positive 2019 1,227
TX_NEW 40-49, Female, Positive 2019 15
TX_NEW 40-49, Male, Positive 2019 417
TX_NEW Breastfeeding status 2019 227
TX_NEW By Age/Sex: <1 2019 117
TX_NEW By Age/Sex: 1-9 2019 77
TX_NEW By Age/Sex: 10-14 Female 2019 26
TX_NEW By Age/Sex: 10-14 Male 2019 20
TX_NEW By Age/Sex: 15-19 Female 2019 376
TX_NEW By Age/Sex: 15-19 Male 2019 468
TX_NEW By Age/Sex: 20-24 Female 2019 1,299
TX_NEW By Age/Sex: 20-24 Male 2019 1,503
TX_NEW By Age/Sex: 50+ Female 2019 7
TX_NEW By Age/Sex: 50+ Male 2019 203
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 8,091
TX_NEW Pregnancy status 2019 696
TX_NEW Sum of Age/Sex disaggregates 2019 3,902
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 70,607
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 2,996
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 1,959
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 42,527
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 23,125
TX_PVLS_den Denominator: Indication: Routine 2019 70,607
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 2,521
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 6,291
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 8,812
TX_RET Numerator by Status: Breastfeeding 2019 198
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 10,322
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 7,197
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 3,125
TX_RET_den Denominator by Status: Breastfeeding 2019 261
TX_RET_den Denominator by Status: Pregnant 2019 648
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 73,331
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 3,425
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 3,072
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 47,411
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 19,423
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 2,999
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 263
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 3,369
VMMC_CIRC By Age: 0-60 days 2019 494
VMMC_CIRC By Age: 10-14 2019 11,970
VMMC_CIRC By Age: 15-19 2019 4,682
VMMC_CIRC By Age: 20-24 2019 1,697
VMMC_CIRC By Age: 25-29 2019 670
VMMC_CIRC By Age: 50+ 2019 7
VMMC_CIRC By circumcision technique: Surgical VMMC 2019 19,520
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2019 19,520
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2019 19,026
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2019 18,356
Cross Cutting Budget Categories and Known Amounts Total: $2,307,122
Key Populations: MSM and TG $67,255
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: Sex Workers $35,415
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Gender: Gender Equality $8,300
Equity in HIV prevention, care, treatment and support
Implementation
Capacity building
Changing harmful gender norms and promoting positive gender norms
Implementation
Capacity building
Motor Vehicles: Purchased $175,359
Human Resources for Health $2,020,793